Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
19 sept. 2023 08h00 HE
|
Tempest Therapeutics
BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted...
Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference
05 sept. 2023 08h00 HE
|
Tempest Therapeutics
BRISBANE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted...
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
10 août 2023 16h13 HE
|
Tempest Therapeutics
BRISBANE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted...
Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together
19 juil. 2023 08h00 HE
|
Tempest Therapeutics
In vitro and in vivo data show significant increased potency by blocking prostaglandin PGE2 signaling through both EP2 and EP4 receptors compared to celecoxib or single EP4 antagonists TPST-1495...
Tempest to Present at the Jefferies Global Healthcare Conference
31 mai 2023 16h05 HE
|
Tempest Therapeutics
BRISBANE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and...
Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers
25 mai 2023 17h00 HE
|
Tempest Therapeutics
• Data show tumor shrinkage and prolonged disease control in both monotherapy and in combination with pembrolizumab • Oral, once-daily cancer treatment well tolerated with a manageable safety...
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 mai 2023 16h05 HE
|
Tempest Therapeutics
BRISBANE, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and...
Tempest Reports First Quarter 2023 Financial Results and Provides Business Update
10 mai 2023 16h15 HE
|
Tempest Therapeutics
BRISBANE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and...
Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
28 avr. 2023 08h00 HE
|
Tempest Therapeutics
Positive randomized data with TPST-1120 combined with atezolizumab + bevacizumab compared head-to-head with atezolizumab + bevacizumabThe addition of TPST-1120 resulted in a clinically-meaningful...
Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
27 avr. 2023 16h58 HE
|
Tempest Therapeutics
BRISBANE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted...